FENC - Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences | Benzinga
RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC, TSX:FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.
Presentation Details:
Event: Jefferies London Healthcare Conference in London, UK
Date: November 16, 2023
Time: Company Presentation at 5:00 a.m. ET / 10:00 a.m. GMT
Event: Craig Hallum Alpha Select Conference in New York City
Date: November 16, 2023
Time: Company One-On-One Investor Meetings
For additional information, please visit the investor relations section of the Company's website at:
https://investors.fennecpharma.com/events-and-presentations/events
PEDMARK® (sodium thiosulfate injection)
PEDMARK® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.
In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown ...